Status:
COMPLETED
Ginkgo Biloba for the Treatment of Vitiligo Vulgaris in Adolescents
Lead Sponsor:
University of Toronto
Collaborating Sponsors:
Canadian Interdisciplinary Network Complementary & Alternative Medicine Research
Conditions:
Vitiligo Vulgaris
Eligibility:
All Genders
12-18 years
Phase:
PHASE1
Brief Summary
Vitiligo is a common hypopigmentation disorder with significant psychological impact if occurring before adulthood. One study investigating the use of Ginkgo biloba for the treatment of vitiligo in ad...
Eligibility Criteria
Inclusion
- • males and females
- 12 to 18 years old
- self selected candidates identifying themselves to suffer with vitiligo vulgaris of any duration
- minimum VASI score of 4, no maximum score (corresponding to a 3cm2 completely (100%) depigmented lesion, or a 6cm2 50% depigmented lesion)
- stable or progressing vitiligo
- mentally competent subjects able to adhere to the given protocol and treatments administered as interventions
- normal on physical examination at the pre-study intake, and in the case of abnormalities the health care practitioner considers them to be clinically insignificant
- written and informed consent
- the potential candidate must have a family doctor that they have seen in the last 12 months
- negative pregnancy test for menstruating women and if sexually active, a willingness to practice adequate birth control for the duration of the trial
- diagnosis of vitiligo confirmed by supervising medical doctor
Exclusion
- • use of medications contraindicated with Ginkgo biloba:
- daily use of acetylsalicylic acid, ibuprofen, NSAIDs, fish oils, vitamin E
- any prescription or use of blood thinners, anticoagulants, anti-platelet drugs, pentoxifylline, clotting factor replacements, antihypertensive medications, Thiazide diuretics, Acetylcholinesterase inhibitors, anticonvulsants, hypoglycemic agents, MAOI, SSRI, Nifedipine, Papaverine, Yohimgine, Sildenafil
- history of diabetes, seizures, haemophilia
- allergy or sensitivity to Ginkgo biloba or other constituents in the capsule
- any treatment for vitiligo within the last 2 months
- current use of Ginkgo biloba or within the last 2 months
- mentally or physically incapacitated such that assent or informed consent cannot be obtained.
- any history or other condition which the study physician regards as clinically significant to the study
- a major illness considered to be clinically significant by the study physician within 2 months of the study start date
- current participation in another intervention trial.
- pregnancy or intent to become pregnant in the next 4 months
- current alcoholism or substance abuse.
- current history of tumors, any history of skin cancer
- any current serious disorders determined to be clinically significant to the study.
- breast feeding women
- no prior skin grafts or surgeries, or scheduled surgeries of any kind.
- any abnormalities on the INR, PTT, or CBC tests at baseline
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00907062
Start Date
May 1 2009
End Date
November 1 2009
Last Update
July 8 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Noumena Naturopathic Health Clinic
Mississauga, Ontario, Canada, L5H 1H2